Tracer library / [225Ac]Ac-HuM195

[225Ac]Ac-HuM195

Also written as HuM195; [225Ac]Ac-HuM195; lintuzumab
Radionuclide
Ac-225
Modality
—
Production route
—
Stage
Preclinical
Syntheses indexed
0
Leukemia (acute and chronic)Dosimetry and biodistribution studies

What it is

Compound class
Humanized anti-CD33 monoclonal antibody radioimmunoconjugate (alpha-emitting nanogenerator)
Target / mechanism
CD33 (early myeloid antigen) PMID 14734685
Clinical application
Myeloid leukemias (targeted therapy of CD33-positive leukemia cells) PMID 7493368
Theranostic pair
—

Published syntheses

No synthesis has been parsed for this agent yet.

Clinical literature

Clinical studies in the indexed corpus, ordered by design (multicentre, prospective, retrospective, others, case reports last) and then by year. Titles and links only, as published; this is not a summary of the evidence.

  1. Radiolabeled anti-CD33 monoclonal antibody M195 for myeloid leukemias.
    1995 · Cancer Res · Clinical study

Need this precursor?We can point you to suppliers for [225Ac]Ac-HuM195, or handle the enquiry for you.

Get in touch

Notes

Added at stage 39 (2026-09-27) from a reverse search of the PubMed corpus's own unattached articles (articles that named a real compound not yet in this reference): 3 article(s) found under this name, not yet individually researched. Target/mechanism, clinical application, indications, approval, modality, stage and production route are intentionally left empty. PMIDs: 7493368, 14734685, 40957448. Stage set/updated at stage 39 from PMID 14734685: 'Cynomolgus monkeys were used to evaluate the toxicity of prototype (225)Ac nanogenerators.'.